Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 4
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13270
Abstract: The oncogenic role of ephrin type‐B receptor 4 (EPHB4) has been reported in many types of tumors, including chronic myeloid leukemia (CML). Here, we found that CML patients have a higher EPHB4 expression level than… read more here.
Keywords: imatinib; growth; ephrin type; vandetanib ... See more keywords
[OA164] Vandetanib may act as a radiosensitiser for 177Lu-octreotate treatment of medullary thyroid cancer
Sign Up to like & getrecommendations! Published in 2018 at "Physica Medica"
DOI: 10.1016/j.ejmp.2018.06.236
Abstract: Purpose Medullary thyroid cancer (MTC) is a very rare type of cancer. Most patients diagnosed with MTC present with metastatic disease. Therefore, surgical resection is often complemented by external beam radiotherapy (EBRT) or the use… read more here.
Keywords: medullary thyroid; treatment; thyroid cancer; vandetanib ... See more keywords
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0986
Abstract: Purpose: Gastrointestinal stromal tumors (GIST) are resistant to cytotoxic chemotherapy and radiotherapy. Most GIST in children are wild-type for KIT and PDGFRA (WT GIST) and deficient in expression of succinate dehydrogenase (dSDH GIST). We tested… read more here.
Keywords: dsdh gist; partial complete; succinate dehydrogenase; gastrointestinal stromal ... See more keywords
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.14911
Abstract: Medulloblastoma is comprised of at least four molecular subgroups with distinct clinical outcome (WHO classification 2016). SHH-TP53-mutated as well as MYC-amplified Non-WNT/Non-SHH medulloblastoma show the worst prognosis. Here we present evidence that single application of… read more here.
Keywords: pi3k; shh tp53; medulloblastoma; anti neoplastic ... See more keywords